Dyno Therapeutics Announces Ocular Collaboration With Novartis To Develop Improved Gene Therapies With Aav Vectors Based On Ai Technology
Dyno Therapeutics, A Biotechnology Company Applying Artificial Intelligence (Ai) To Gene Therapy, Today Announced A Collaboration With Novartis To Develop Improved Adeno-Associated Virus (Aav) Vectors For Research, Development, And Commercialization Of Gene Therapies For Ocular Diseases. The Partnership Will Allow The Parties To Utilize Dyno&Rsquo;S Capsidmap&Trade; Artificial Intelligence Platform Along With Novartis Expertise In Gene Therapy Development And Global Commercialization To Deliver Innovative Gene Therapies To Patients With Serious Diseases Of The Eye.&Ldquo;We Are Delighted To Be Collaborating With Novartis,&Rdquo; Stated Eric D. Kelsic, Ph.D., Ceo And Co

Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!